[Event] Japan's Regenerative Medicine Market: Opportunities for Minnesota Companies
Jan 23, 2017
Hear how recent regulatory reform has opened Japan's regenerative medicine market to foreign companies. Guest speakers include Gil van Bokkelen,
Chairman and CEO of Athersys, Inc.
|
DATE & TIME
VENUE
REGISTER Cost: FREE http://bit.ly/2jF6kuO
|
3:30 PM 4:00 PM
4:05 PM
4:25 PM
5:05 PM
5:15 PM 6:30 PM |
Kathleen Motzenbecker, Sr. Vice President, Japan Regenerative Medicine Market Overview
Ralph Inforzato, Executive Director, Robert Corder, Project Coordinator, JETRO Chicago Athersys and Japan Gil Van Bokkelen, Chairman and CEO, Athersys, Inc. Q&A Closing Remarks Ichiro Sone, Chief Executive Director, JETRO Chicago
Kathleen Motzenbecker, Sr. Vice President, Networking Reception Adjournment |
EVENT SUMMARY
In 2014, the Japanese government implemented major regulatory reforms which dramatically shortened the approval process for regenerative therapies. The government also now allows businesses other than hospitals and research institutes to produce cells for medical use. With the world's fastest approval process, specifically designed for regenerative medicine, foreign companies are now considering Japan as a potential location for clinical trials.
There are also new business opportunities emerging for foreign companies as Japan develops its regenerative medicine-related infrastructure. Representatives from JETRO, the Japanese government’s economic development organization, will detail the status of these reforms and talk about how American companies are taking advantage of Japan’s new business climate. Athersys, Inc. Chairman and CEO Gil van Bokkelen will also share his views on the Japanese market and his discuss his company’s strategic partnership with the Japanese company Healios.
SUPPORTING ORGANIZATIONS
